Suppr超能文献

肝移植作为不可切除结直肠癌肝转移患者的一种治疗方法。

Liver Transplantation as a Curative Approach for Patients With Nonresectable Colorectal Liver Metastases.

机构信息

From the Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

出版信息

Exp Clin Transplant. 2022 Feb;20(2):113-121. doi: 10.6002/ect.2021.0421.

Abstract

OBJECTIVES

Liver transplant is emerging as a potential treatment option for patients with isolated colorectal liver metastasis. In this review article, we analyzed the published literature on liver transplant outcomes in such patients.

MATERIALS AND METHODS

Four prospective studies documenting the clinical outcomes in patients with colorectal liver metastasis who underwent liver transplant were analyzed to study the feasibility of liver transplant in such patients.

RESULTS

The SECA-II trial demonstrated the highest overall survival of 100%, 83%, and 83% at 1, 3, and 5 years, respectively, and disease-free survival of 53%, 44%, and 35%, respectively, with a narrow inclusion criterion. Conversely, extended criteria for selection and donors in arm D of the same trial resulted in median overall survival and disease-free survival of 18 and 4 months, respectively.

CONCLUSIONS

Liver transplant provided more prolonged overall survival compared with other therapeutic modalities. Patients with isolated colorectal liver metastasis of less aggressive biology, good performance status, at least 6 weeks of chemotherapy, low clinical risk scores, and negative nodal disease should be considered for patient selection. Moreover, exclusion criteria consisting of patients with the right-sided primary tumor, less than 3 years to liver transplant after diagnosis, and elevation of carbohydrate antigen (CA19-9) in the presence of BRAF mutation should be explored.

摘要

目的

肝移植作为一种治疗孤立性结直肠肝转移的潜在方法正在出现。在这篇综述文章中,我们分析了已发表的关于此类患者接受肝移植的文献,以研究肝移植在这些患者中的可行性。

材料和方法

分析了四项前瞻性研究,这些研究记录了接受肝移植的结直肠肝转移患者的临床结果,以研究肝移植在这些患者中的可行性。

结果

SECA-II 试验显示出最高的总体生存率,分别为 100%、83%和 83%,1、3 和 5 年无病生存率分别为 53%、44%和 35%,纳入标准严格。相比之下,同一试验的 D 臂中对选择和供体的扩展标准导致中位总生存率和无病生存率分别为 18 个月和 4 个月。

结论

与其他治疗方法相比,肝移植提供了更持久的总体生存率。对于具有侵袭性生物学、良好表现状态、至少 6 周化疗、低临床风险评分和阴性淋巴结疾病的孤立性结直肠肝转移患者,应考虑进行患者选择。此外,还应探索排除标准,包括右半原发性肿瘤、诊断后至肝移植的时间少于 3 年以及存在 BRAF 突变时糖抗原(CA19-9)升高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验